Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Watanabe
Hiroshi
H
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000959:Antihypertensive Agents / Q000627:therapeutic use; D006152:Cyclic GMP / Q000378:metabolism / Q000502:physiology; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D011464:Epoprostenol / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D010726:Phosphodiesterase Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D000959:Antihypertensive Agents; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D011464:Epoprostenol; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; D006152:Cyclic GMP